What is a PGX All/General Medicine Panel?
A PGX (pharmacogenomic) All/General Medicine panel is a multi-gene genetic test that analyzes multiple pharmacogenes simultaneously to predict how a patient will metabolize and respond to commonly prescribed medications across various therapeutic areas, with results stored preemptively in the medical record for use at the point of prescribing. 1, 2
Panel Composition and Structure
PGX panels are designed to be medication-category agnostic, meaning they test all actionable pharmacogenes rather than focusing on a single disease or drug class 1. These panels typically include:
- 14-58 germline variant alleles across key pharmacogenes 3
- Core genes commonly tested: CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT, NUDT15, VKORC1, UGT1A1, and HLA genes (HLA-A, HLA-B) 2, 3
- Technology platforms: Commercial arrays, PCR-based bundles, next-generation sequencing, or hybrid approaches 1
Clinical Rationale for Panel Testing
The evidence supporting broad panel testing is compelling:
- Over 98% of individuals carry at least one actionable pharmacogenetic variant 1, 4
- 50-65% of patients aged 40-64 receive at least one pharmacogenomically actionable medication within 4-5 years 1
- 24% of new prescriptions involving actionable medications represent a gene-drug interaction requiring intervention 1
How Results Are Used
Panel results are interpreted using standardized phenotype classifications 2:
- Poor metabolizer (PM)
- Intermediate metabolizer (IM)
- Normal metabolizer (NM)
- Rapid metabolizer (RM)
- Ultrarapid metabolizer (UM)
Reports must include 2:
- Genotype and metabolizer phenotypes
- List of medications affected by identified genotypes
- Generalized statements about alternative therapies when indicated
- References to FDA tables and CPIC guidelines for actionable decisions
- Critical caveat: Drug-drug interactions can alter metabolizer phenotypes (e.g., CYP2D6 inhibitors converting normal metabolizers to poor metabolizers) 2
Preemptive vs. Reactive Testing Model
The key advantage of panel testing is the preemptive approach: Results are obtained once and stored in the electronic health record, available immediately when any relevant medication is prescribed, eliminating turnaround time delays 1. This contrasts with reactive single-gene testing ordered after a medication decision is made.
Important Limitations and Caveats
Technical challenges exist for certain genes 1:
- CYP2D6 requires specialized detection methods due to gene duplications and rearrangements
- HLA genes present technical complexity
- Not all variants of uncertain significance are reported by all laboratories
Interpretation complexity 1:
- Some centers return all results to the medical record
- Others mask genes/variants with uncertain actionability
- Only genes with CPIC or DPWG guideline recommendations may be reported at some institutions
Clinical reports should NOT provide patient-specific dosing recommendations—only general guidance that prescribers must interpret in the context of other clinical factors 2.
Cost-Effectiveness Evidence
Limited but emerging data suggests cost-effectiveness: A 30-gene preemptive panel including CYP2C19-clopidogrel, CYP2C9/VKORC1-warfarin, DPYD-fluoropyrimidines, and SLCO1B1-statins was cost-effective compared to usual care 1. Recent real-world data showed a trend toward $1,827 per member per year savings in total healthcare costs 5.
Clinical Implementation
Panels are validated for routine clinical use with accuracy >96%, sensitivity 100%, and specificity >95% when properly implemented 6, 7. The testing is feasible in community-based settings and increasingly adopted in primary care for Medicare populations with polypharmacy 5.